Search Results

Filter
  • 1-10 of  487 results for ""RITUXIMAB""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.

  • Authors : McKay KA; Neuro Division, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Centre for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Subjects: COVID-19*/COVID-19*/COVID-19*/complications ; Hospitalization* ; Severity of Illness Index*

  • Source: JAMA network open [JAMA Netw Open] 2021 Dec 01; Vol. 4 (12), pp. e2136697. Date of Electronic Publication: 2021 Dec 01.Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet

Record details

×
Academic Journal

Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.

  • Authors : Brånvall E; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.; Department of Medicine, Division of Hematology, Capio S:t Görans Hospital, Stockholm, Sweden.

Subjects: Hydroxymethylglutaryl-CoA Reductase Inhibitors/Hydroxymethylglutaryl-CoA Reductase Inhibitors/Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/*mortality ; Lymphoma, Non-Hodgkin/Lymphoma, Non-Hodgkin/Lymphoma, Non-Hodgkin/*mortality

  • Source: British journal of haematology [Br J Haematol] 2021 Nov; Vol. 195 (4), pp. 552-560. Date of Electronic Publication: 2021 Jul 31.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.

  • Authors : Razaz N; From the Department of Medicine (N.R., T.F.), Solna, Clinical Epidemiology Division, Karolinska Institutet; Department of Clinical Neuroscience (F.P., K.A.M., K.F.), Karolinska Institutet

Subjects: Outcome Assessment, Health Care* ; Registries*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*pharmacology

  • Source: Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2020 Oct 21; Vol. 7 (6). Date of Electronic Publication: 2020 Oct 21 (Print Publication: Publisher: Wolters Kluwer Health/Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101636388 Publication Model: Electronic-Print

Record details

×
Academic Journal

Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.

Subjects: Outcome Assessment, Health Care*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*pharmacology ; Myasthenia Gravis/Myasthenia Gravis/Myasthenia Gravis/*drug therapy

  • Source: JAMA neurology [JAMA Neurol] 2020 Aug 01; Vol. 77 (8), pp. 974-981.Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Rituximab in multiple sclerosis at general hospital level.

  • Authors : Hellgren J; Medical Faculty, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.; Risedal A

Subjects: Hospitals, General/Hospitals, General/Hospitals, General/*methods ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Multiple Sclerosis/Multiple Sclerosis/Multiple Sclerosis/*diagnostic imaging

  • Source: Acta neurologica Scandinavica [Acta Neurol Scand] 2020 Jun; Vol. 141 (6), pp. 491-499. Date of Electronic Publication: 2020 Feb 06.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 0370336 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.

  • Authors : Alping P; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Subjects: Fingolimod Hydrochloride/Fingolimod Hydrochloride/Fingolimod Hydrochloride/*adverse effects ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*adverse effects ; Multiple Sclerosis/Multiple Sclerosis/Multiple Sclerosis/*drug therapy

  • Source: Annals of neurology [Ann Neurol] 2020 May; Vol. 87 (5), pp. 688-699. Date of Electronic Publication: 2020 Mar 09.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

  • Authors : Boremalm M; Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå.; Juto A

Subjects: Fingolimod Hydrochloride/Fingolimod Hydrochloride/Fingolimod Hydrochloride/*therapeutic use ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/*drug therapy

  • Source: European journal of neurology [Eur J Neurol] 2019 Aug; Vol. 26 (8), pp. 1060-1067. Date of Electronic Publication: 2019 Mar 12.Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331

Record details

×
Academic Journal

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

  • Authors : Luna G; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.; Alping P

Subjects: Fingolimod Hydrochloride/Fingolimod Hydrochloride/Fingolimod Hydrochloride/*therapeutic use ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Infections/Infections/Infections/*epidemiology

  • Source: JAMA neurology [JAMA Neurol] 2020 Feb 01; Vol. 77 (2), pp. 184-191.Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.

  • Authors : Spelman T; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden/Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.; Frisell T

Subjects: Glatiramer Acetate/Glatiramer Acetate/Glatiramer Acetate/*therapeutic use ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Interferon-beta/Interferon-beta/Interferon-beta/*therapeutic use

  • Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2018 Jul; Vol. 24 (8), pp. 1087-1095. Date of Electronic Publication: 2017 Jun 26.Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.

Subjects: Abatacept/Abatacept/Abatacept/*adverse effects ; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*adverse effects ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*adverse effects

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2019 Mar; Vol. 78 (3), pp. 320-327. Date of Electronic Publication: 2019 Jan 05.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060

Record details

×
  • 1-10 of  487 results for ""RITUXIMAB""